Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS¬, to optimize the delivery of previously approved drug products. The CompanyÍs lead product candidates, HLD-200 and HLD-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease _ inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS¬ is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing control of ADHD symptoms immediately upon wakening and throughout the day. Ironshore Pharmaceuticals & Development, Inc. is a wholly owned subsidiary of Highland Therapeutics, Inc.